Q2 Earnings Season Breaks Its Own Rules as Share-Price Reactions Decouple From Results

Post-earnings share-price reactions are becoming increasingly disconnected from reported fundamentals during what is being characterized as a historic Q2 season by reporting volume. The dislocation reflects crowded positioning, elevated options-implied moves and a market more focused on forward capital-allocation signals than on trailing beats and misses — conditions under which event-driven strategies systematically underperform their backtests. AbbVie offers a clean illustration of fundamentals accruing beneath the noise. Management now guides to $12.7 billion in neuroscience sales for the year, establishing a second blockbuster franchise alongside the immunology portfolio and materially de-risking the post-Humira narrative that has anchored the bear case. The market's gradual recognition of this transition contrasts sharply with the violent, often direction-agnostic repricings occurring elsewhere on the tape. Applied Materials presents the mirror image: records on nearly every line item, upgraded guidance, and a share price more than 25% below its high — the equity is being priced for cycle exhaustion despite management signaling extension. Insider activity provides a modest counterweight to broad optimism, with PubMatic chief executive Rajeev Goel selling $3.75 million in stock and Scholastic director Kaya Henderson disposing of $130,812. Fund commentary flowing in from Diamond Hill, American Century, Thornburg, Lord Abbett and Brown Advisory converges on a similar conclusion: dispersion, not direction, is the defining feature of this market, and security selection is reasserting itself as the primary source of alpha.